BETA

Beta Drugs Share Price

₹1,793.25 -4.45 (-0.25%)

12 Jun, 2025 21:50

SIP TrendupStart SIP in BETA

Start SIP

Performance

  • Low
  • ₹1,780
  • High
  • ₹1,832
  • 52 Week Low
  • ₹1,119
  • 52 Week High
  • ₹2,215
  • Open Price₹1,809
  • Previous Close₹1,798
  • Volume4,410

Investment Returns

  • Over 1 Month + 3.62%
  • Over 3 Month + 11.42%
  • Over 6 Month -15.76%
  • Over 1 Year + 52.62%
SIP Lightning

Smart Investing Starts Here Start SIP with Beta Drugs for Steady Growth!

Invest Now

Beta Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 117.3
  • PEG Ratio
  • -
  • Market Cap Cr
  • 1,810
  • P/B Ratio
  • 14.1
  • Average True Range
  • 67.86
  • EPS
  • 45.36
  • Dividend Yield
  • 0
  • MACD Signal
  • 9.66
  • RSI
  • 46.34
  • MFI
  • 44.73

Beta Drugs Financials

Beta Drugs Technicals

EMA & SMA

Current Price
₹1,793.25
-4.45 (-0.25%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹1,827.33
  • 50 Day
  • ₹1,815.22
  • 100 Day
  • ₹1,797.73
  • 200 Day
  • ₹1,719.67

Resistance and Support

1801.72 Pivot Speed
  • R3 1,875.33
  • R2 1,853.62
  • R1 1,823.43
  • S1 1,771.53
  • S2 1,749.82
  • S3 1,719.63

What's your outlook on Beta Drugs?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Beta Drugs Ltd. specializes in manufacturing and marketing oncology pharmaceutical products, including injectable and oral formulations. The company operates advanced manufacturing facilities in India, providing high-quality cancer treatment solutions to domestic and international markets.

Beta Drugs has an operating revenue of Rs. 799.34 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 9% is okay, ROE of 11% is good. The company has a debt to equity of 96%, which is bit higher. The stock from a technical standpoint is trading close to its key moving averages, around -0% and 1% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at D which indicates heavy supply, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Beta Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-15 Audited Results
2025-03-27 Others To consider other business matters :- The allotment of 4,80,693 fully paid-up equity shares of the Company of face value of INR 10 each, under Bonus Issue. issue of equity shares in the ratio of 1:20 of Rs. 10/-.
2025-02-05 Issue of Bonus & Others To consider other business matters. issue of equity shares in the ratio of 1:20 of Rs. 10/-.
2024-11-06 Quarterly Results
2024-10-19 To consider Fund Raising
Date Purpose Remarks
2025-03-26 Bonus Rs.0.00 issue of equity shares in the ratio of 1:20 of Rs. 10/-.

Beta Drugs F&O

Beta Drugs Shareholding Pattern

66.73%
0.9%
21.81%
10.56%

About Beta Drugs

  • NSE Symbol
  • BETA
  • BSE Symbol
  • 531481
  • Chairperson & Managing Director
  • Mr. Rahul Batra
  • ISIN
  • INE351Y01019

Similar Stocks to Beta Drugs

Beta Drugs FAQs

Beta Drugs share price is ₹1,793 As on 12 June, 2025 | 21:36

The Market Cap of Beta Drugs is ₹1810.2 Cr As on 12 June, 2025 | 21:36

The P/E ratio of Beta Drugs is 117.3 As on 12 June, 2025 | 21:36

The PB ratio of Beta Drugs is 14.1 As on 12 June, 2025 | 21:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23